NAUT vs QBTS

Analysts rate Nautilus Biotechnology, Inc.

(NAUT) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, D-Wave Quantum Inc.

(QBTS) delivered a total return of +122. 2%, compared to -71. 3% for Nautilus Biotechnology, Inc. (NAUT). Over 10 years, the gap is even starker: QBTS returned +116. 7% versus NAUT's -72. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Nautilus Biotechnology, Inc.

(NAUT) is the lower-risk stock at 1. 82β versus D-Wave Quantum Inc. 's 3. 48β — meaning QBTS is approximately 92% more volatile than NAUT relative to the S&P 500. On balance sheet safety, D-Wave Quantum Inc. (QBTS) carries a lower debt/equity ratio of 1% versus 19% for Nautilus Biotechnology, Inc. — giving it more financial flexibility in a downturn.

On earnings-per-share growth, the picture is similar: Nautilus Biotechnology, Inc.

grew EPS 16. 1% year-over-year, compared to -48. 0% for D-Wave Quantum Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Nautilus Biotechnology, Inc.

(NAUT) is the more profitable company, earning 0. 0% net margin versus -1444. 1% for D-Wave Quantum Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NAUT leads at 0. 0% versus -408. 2% for QBTS. At the gross margin level — before operating expenses — QBTS leads at 82. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Nautilus Biotechnology, Inc.

(NAUT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. D-Wave Quantum Inc. (QBTS) carries a higher beta of 3. 48 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (NAUT: -72. 4%, QBTS: +116. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (NAUT (Healthcare) and QBTS (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: NAUT is a small-cap quality compounder stock; QBTS is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.